US 11,752,179 B2
Medical use of probiotics
Andrea Biffi, Urgnano (IT); Walter Fiore, Atrani (IT); and Ruggero Rossi, Milan (IT)
Assigned to ALFASIGMA S.P.A., Bologna (IT)
Appl. No. 16/308,330
Filed by ALFASIGMA S.P.A., Bologna (IT)
PCT Filed Jun. 8, 2017, PCT No. PCT/IB2017/053389
§ 371(c)(1), (2) Date Dec. 7, 2018,
PCT Pub. No. WO2017/212433, PCT Pub. Date Dec. 14, 2017.
Claims priority of application No. 102016000058515 (IT), filed on Jun. 8, 2016.
Prior Publication US 2019/0290706 A1, Sep. 26, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/747 (2015.01); A61K 36/064 (2006.01); A61P 1/00 (2006.01); A61K 9/14 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 9/00 (2006.01); A61K 35/745 (2015.01)
CPC A61K 35/747 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0053 (2013.01); A61K 35/745 (2013.01); A61K 36/064 (2013.01); A61P 1/00 (2018.01)] 16 Claims
 
1. A method for treating abdominal pain and/or discomfort, comprising
administering to a patient suffering from Irritable Bowel Syndrome (IBS) a composition comprising Lactobacillus paracasei DG strain deposited with the deposit number CNCM 1-1572, the administering performed to treat the abdominal pain and/or discomfort associated with the IBS,
wherein the Irritable Bowel Syndrome (IBS) is selected from IBS-C and IBS-U.